Page 222 - Multidisipliner Covid 19

BÖLÜM 12

roquine in the treatment of novel coronavirus p. Expert consensus on
chloroquine phosphate for the treatment of novel coronavirus pneumo-
nia. Chin J Tuberc Respir Dis. 2020;43(3):185–8.
21. Marmor MF, Kellner U, Lai TY, Melles RB, Mieler WF. Recommendations
on screening for Chloroquine and Hydroxychloroquine retinopathy.
Ophthalmology. 2016; 123(6):1386–94.
22. Meo SA, Klonoff DC, Akram J. Efficacy of chloroquine and hydroxychlo-
roquine in the treatment of COVID-19. European Review for Medical and
Pharmacological Sciences. 2020; 24: 4539-4547.
23. Romão VC, Cruz-Machado AR, Fonseca JE. No evidence so far on the
protective effect of hydroxychloroquine to prevent COVID-19: response
to the comment by Joob and Wiwanitkit. Ann Rheum Dis Month. 2020;
217665:1-11. doi: 10.1136/annrheumdis-2020-217665.
24. Yao TT, Qian JD, Zhu WY, Wang Y, Wang GQ. A systematic review of
lopinavir therapy for SARS coronavirus and MERS coronavirus-a possi-
ble reference for coronavirus disease-19 treatment option. J Med Virol.
2020;92(6):556-563. doi: 10.1002/jmv.25729.
25. Cao B, Wang Y, Wen D, et al. A trial of lopinavir-ritonavir in adults hos-
pitalized with severe Covid-19. N Engl J Med. 2020;382(19): 1787-99.
26. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality
of adult inpatients with COVID-19 in Wuhan, China: a retrospective
cohort study. Lancet. 2020;395(10229):1054–62.
27. Li Y, Xie Z, Lin W, et al. An exploratory randomized controlled study
on the efficacy and safety of lopinavir/ritonavir or arbidol treating
adult patients hospitalized with mild/moderate COVID-19 (ELACOI).
medrxiv. 2020. https://www.medrxiv.org/ content/10.1101/2020.03.19.
20038984v2.
28. Wu J, Li W, Shi X, et al. Early antiviral treatment contributes to alleviate
the severity and improve the prognosis of patients With novel corona-
virus Disease (COVID-19). Journal of Internal Medicine. 2020;1-11. doi:
10.1111/joim.13063.
29. Kaplan SS, Hicks CB. Safety and antiviral activity of lopinavir/ritonavir-
based therapy in human immunodeficiency virus type 1 (HIV-1) infec-
tion. J Antimicrob Chemother. 2005;56(2):273–6.
30. Kadam RU, Wilson IA. Structural basis of influenza virus fusion inhibi-
tion by the antiviral drug Arbidol. Proc Natl Acad Sci U S A.2017;114(2):
206- 214. doi:10.1073/pnas.1617020114.

221